Loading...
Ajanta Pharma Limited — Captopril Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #2 for Captopril · $1.3M export value · DGFT Verified
Ajanta Pharma Limited is the #2 Indian exporter of Captopril with $1.3M in export value and 60 verified shipments. Ajanta Pharma Limited holds a 10.5% market share in Captopril exports across 1 countries. The company exports 37 pharmaceutical products worth $116.1M across 17 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| TANZANIA | $1.9M | 37 | 31.9% |
| UNITED STATES | $1.3M | 65 | 22.6% |
| BELGIUM | $686.2K | 31 | 11.8% |
| DOMINICAN REPUBLIC | $295.0K | 48 | 5.1% |
| SOUTH AFRICA | $280.9K | 24 | 4.8% |
| CONGO DR | $270.2K | 19 | 4.7% |
| VENEZUELA | $215.8K | 24 | 3.7% |
| RWANDA | $182.4K | 5 | 3.1% |
| UGANDA | $158.8K | 16 | 2.7% |
| ANGOLA | $151.8K | 52 | 2.6% |
India exports Captopril to 63 countries. The top destination is TANZANIA (31.9%), followed by UNITED STATES and BELGIUM.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| AJANTA PHARMA USA INC. C/O RXCROSSR | UNITED STATES | $1.1M | 42 |
| HEKO PHARMACY LTD | TANZANIA | $336.7K | 10 |
| UNIQUE PHARMA, | CONGO DR | $232.1K | 5 |
| M.S.D | TANZANIA | $200.0K | 4 |
| EXPHAR SANIVELLES SUD ZONE II THINES | BELGIUM | $162.8K | 9 |
| MEDICAL STORES DEPARTMENT | TANZANIA |
India exported $4.5M worth of Captopril through 517 shipments from 109 suppliers to 63 countries, serving 170 buyers globally. Ajanta Pharma Limited contributes $1.3M to this total, accounting for 10.5% of India's Captopril exports.
Ajanta Pharma Limited's average Captopril shipment value is $21.7K per consignment, based on 60 shipments totaling $1.3M.
Ajanta Pharma Limited ranks #2 among 109 Indian Captopril exporters with a 10.5% market share. The top 3 exporters are AJANTA PHARMA LIMITED ($1.3M), LINCOLN PHARMACEUTICALS LTD ($1.0M), GRACURE PHARMACEUTICALS LIMITED ($686.2K). Ajanta Pharma Limited processed 60 shipments to 1 destination countries.
What Ajanta Pharma Limited must comply with to export Captopril to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | AJANTA PHARMA LIMITED ★ | $1.3M | 60 | 1 | $21.7K |
| 1 | LINCOLN PHARMACEUTICALS LTD | $1.0M | 20 | 2 | $50.0K |
| 3 | GRACURE PHARMACEUTICALS LIMITED | $686.2K | 31 | 1 | $22.1K |
Ajanta Pharma Limited ranks #2 among 109 Indian Captopril exporters. Average shipment value of $21.7K compared to the market average of $40.9K. The closest competitors by value are LINCOLN PHARMACEUTICALS LTD and GRACURE PHARMACEUTICALS LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 96 | 18.6% |
| JNPT/ NHAVA SHEVA SEA | 42 | 8.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 35 | 6.8% |
| JNPT | 28 | 5.4% |
| AHEMDABAD ICD | 26 | 5.0% |
| SAHAR AIR | 25 | 4.8% |
| Jnpt | 18 | 3.5% |
| PATLI ICD | 18 | 3.5% |
Ajanta Pharma Limited also exports these cardiovascular products. Each links to the detailed product page.
Ajanta Pharma's export operations are intricately linked to global trade routes, making them susceptible to geopolitical tensions. The ongoing Israel-Iran conflict has disrupted shipping lanes in the Red Sea, leading to increased freight costs and extended delivery timelines. Such disruptions pose challenges for Indian pharmaceutical exporters like Ajanta, necessitating adaptive logistics strategies to maintain supply chain integrity. (pharmaceuticalcommerce.com)
Conversely, the US-China trade tensions have opened avenues for Indian pharmaceutical companies to strengthen their foothold in the American market. India's pharmaceutical exports to the US surged by 74% in March 2025, indicating a shift in sourcing preferences. Ajanta Pharma can leverage this trend by emphasizing its compliance with stringent US regulatory standards and offering competitive pricing. (business-standard.com)
In the European Union, adherence to the Falsified Medicines Directive (FMD) is paramount. Indian exporters, including Ajanta, must ensure robust serialization and traceability measures to comply with these regulations. Non-compliance could result in restricted market access, underscoring the importance of investing in advanced tracking systems and quality assurance protocols.
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the US FDA, WHO, and EU GMP setting stringent compliance benchmarks. India has made significant strides in this arena, surpassing the US in the number of FDA-registered generic manufacturing sites, boasting 752 FDA-approved facilities as of 2024. (business-standard.com) Ajanta Pharma's commitment to quality is evident in its adherence to these international standards, facilitating smoother market entry and bolstering its reputation among global stakeholders.
Ajanta Pharma Limited exports 37 products worth $116.1M. Beyond Captopril, top products include Artemether, Amlodipine, Clopidogrel, Rosuvastatin, Montelukast. View the complete Ajanta Pharma Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Captopril — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Ajanta Pharma Limited's Captopril exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Ajanta Pharma Limited
Full Company Profile →
37 products · $116.1M total trade · 17 categories
| $150.0K |
| 3 |
| HEKO PHARMACY LIMITED | TANZANIA | $137.6K | 5 |
| M/S.RWANDA MEDICAL SUPPLY LTD. | RWANDA | $93.5K | 2 |
| BALAXI HEALTHCARE DOMINICANA SRL | DOMINICAN REPUBLIC | $89.5K | 13 |
| AJANTA PHARMA USA INC | UNITED STATES | $71.4K | 5 |
India's Captopril is purchased by 170 buyers worldwide. The top buyer is AJANTA PHARMA USA INC. C/O RXCROSSR (UNITED STATES), followed by HEKO PHARMACY LTD and UNIQUE PHARMA,.
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 63+ countries, 170+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Ajanta Pharma Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Captopril. For current shipment-level data, contact TransData Nexus.